New joint European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension.
暂无分享,去创建一个
[1] I. Bralić. Primary, secondary and tertiary prevention of obesity , 2009 .
[2] C. Mogensen,et al. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes * , 2003, Journal of internal medicine.
[3] J. Staessen,et al. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.
[4] S. Tonstad,et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.
[5] Yutaka Imai,et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement , 2003, Journal of hypertension.
[6] A. Zanchetti,et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? , 2003, Journal of hypertension.
[7] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[8] Bryan Williams,et al. Treating hypertension: it is not how you start but where you end that matters. , 2003, Journal of hypertension.
[9] C. Reid,et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.
[10] N. Kaplan. The meaning of ALLHAT , 2003, Journal of hypertension.
[11] Nancy R Cook,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.
[12] P. Ridker. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.
[13] C. Ballantyne. Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) , 2003 .
[14] B. Pitt,et al. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .
[15] G. Mancia,et al. New year, new challenges. , 2003, Journal of hypertension.
[16] Deeb N Salem,et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.
[17] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[18] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[19] G. Mancia,et al. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.
[20] Majid Ezzati,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[21] N. Wong,et al. Cardiovascular risk evaluation: an inexact science , 2002, Journal of hypertension.
[22] L. Ramsay,et al. Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods , 2002, Journal of hypertension.
[23] A. Zanchetti,et al. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? , 2002, Journal of hypertension.
[24] Michael F O'Rourke,et al. From theory into practice: arterial haemodynamics in clinical hypertension. , 2002, Journal of hypertension.
[25] G. Mancia,et al. Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. , 2002, Journal of hypertension.
[26] Hans L Hillege,et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.
[27] M. Nieminen,et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.
[28] L. Nieman. Diagnostic Tests for Cushing's Syndrome , 2002, Annals of the New York Academy of Sciences.
[29] M. Nieminen,et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.
[30] S. Taddei,et al. Endothelial dysfunction in essential hypertension: clinical implications. , 2002, Journal of hypertension.
[31] A. Zanchetti,et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy , 2002, Journal of hypertension.
[32] G. Mancia,et al. Systolic and diastolic blood pressure control in antihypertensive drug trials. , 2002, Journal of hypertension.
[33] G. Reaven. Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.
[34] M. Nieminen,et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study , 2002, Journal of hypertension.
[35] G. Mancia,et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey , 2002, Journal of hypertension.
[36] C. Tsalamandris,et al. Albumin to creatinine ratio: a screening test with limitations. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] C. Reid,et al. `Reverse white-coat hypertension’ in older hypertensives , 2002, Journal of hypertension.
[38] Steven Snapinn,et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.
[39] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[40] P. Mehler,et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.
[41] B. Williams,et al. Microalbuminuria in essential hypertension: redefining the threshold. , 2002, Journal of hypertension.
[42] J. Blacher,et al. Central Pulse Pressure and Mortality in End-Stage Renal Disease , 2002, Hypertension.
[43] A. Simon,et al. Intima–media thickness: a new tool for diagnosis and treatment of cardiovascular risk , 2002, Journal of hypertension.
[44] C. Mulrow,et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.
[45] J. Staessen,et al. Results of intervention trials of antihypertensive treatment versus placebo, no or lesser treatment , 2002 .
[46] J. Kirkpatrick. Albuminuria and Risk of Cardiovascular Events , Death , and Heart Failure in Diabetic and Nondiabetic Individuals , 2002 .
[47] J. V. van Engelshoven,et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis , 2002 .
[48] D. Levy,et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. , 2002, The New England journal of medicine.
[49] J F Potter,et al. Twenty-four hour systolic blood pressure predicts long-term mortality following acute stroke , 2001, Journal of hypertension.
[50] L. Ruilope,et al. Renal function: the Cinderella of cardiovascular risk profile. , 2001, Journal of the American College of Cardiology.
[51] F. Magrini,et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension , 2001, Journal of hypertension.
[52] A. Zanchetti,et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study , 2001, Journal of hypertension.
[53] G Parati,et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) , 2001, Journal of hypertension.
[54] SalimYusuf,et al. Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001 .
[55] A. Zanchetti,et al. An Italian chart for cardiovascular risk prediction. Its scientific basis. , 2001, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.
[56] M. O'Rourke,et al. Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure Waveform , 2001, Hypertension.
[57] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[58] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[59] MicheleBombelli,et al. Alterations of Cardiac Structure in Patients With Isolated Office, Ambulatory, or Home Hypertension , 2001 .
[60] F. Magrini,et al. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination? , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.
[61] S. Kjeldsen,et al. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men , 2001, Journal of hypertension.
[62] A. Tislér,et al. Tele-monitoring of home blood pressure. , 2001, Blood pressure monitoring.
[63] François Gueyffier,et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.
[64] A. Simon,et al. Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes , 2001, Circulation.
[65] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[66] C. Held,et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.
[67] R. Fagard. Exercise characteristics and the blood pressure response to dynamic physical training. , 2001, Medicine and science in sports and exercise.
[68] A. Zanchetti,et al. Impact of the Gubbio population study on community control of blood pressure and hypertension , 2001, Journal of hypertension.
[69] G. Parati,et al. Blood Pressure Variability: Mechanisms and Clinical Significance , 1990, Journal of Cardiovascular Pharmacology.
[70] J. Ménard,et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study , 2001, Journal of hypertension.
[71] J. Gardin,et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. , 2001, Journal of the American College of Cardiology.
[72] Michael Peel,et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension , 2001, BMJ : British Medical Journal.
[73] P. Ghahramani,et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.
[74] S. Yusuf,et al. Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.
[75] G. Mancia,et al. Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry , 2001, Circulation.
[76] S J Riederer,et al. High-spatial-resolution contrast-enhanced MR angiography of the renal arteries: a prospective comparison with digital subtraction angiography. , 2001, Radiology.
[77] A. Zanchetti,et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.
[78] Emanuela Falaschetti,et al. Association Between Smoking and Blood Pressure: Evidence From the Health Survey for England , 2001, Hypertension.
[79] G. Bray,et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .
[80] O. Melander. Genetic Factors in Hypertension – What is Known and What Does It Mean? , 2001, Blood pressure.
[81] T. Hedner,et al. Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention Trials , 2001, Blood pressure.
[82] H. Crijns,et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial , 1999, Journal of hypertension.
[83] R. Gordon. Diagnostic investigations in primary aldosteronism , 2001 .
[84] E. Eleuteri. [Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[85] C. Schmid,et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.
[86] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[87] D. Henderson-smart,et al. Antiplatelet agents for preventing and treating pre-eclampsia. , 2007, The Cochrane database of systematic reviews.
[88] P. Choyke,et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. , 2000, The Journal of clinical endocrinology and metabolism.
[89] G Parati,et al. Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.
[90] A. Rocchini. Obesity hypertension, salt sensitivity and insulin resistance. , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[91] John S Yudkin,et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.
[92] John S. Scott,et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.
[93] Giuseppe Mancia,et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.
[94] Thomas Hedner,et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.
[95] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[96] R. Schrier,et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.
[97] M. Schroll,et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.
[98] R. Jackson,et al. Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.
[99] Karla Kerlikowske,et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.
[100] P E Puddu,et al. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. , 2000, European heart journal.
[101] E. Vartiainen,et al. Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.
[102] M. Swiet. Maternal blood pressure and birthweight , 2000, The Lancet.
[103] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[104] Eary,et al. CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .
[105] D. Levy,et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.
[106] T. Hedner,et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.
[107] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[108] W. Cushman,et al. The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.
[109] Gianfranco Parati,et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .
[110] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[111] D. Levy,et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.
[112] L. Magee,et al. Fortnightly review: management of hypertension in pregnancy. , 1999, BMJ.
[113] R. Pini,et al. Cardiac and Arterial Target Organ Damage in Adults with Elevated Ambulatory and Normal Office Blood Pressure , 1999, Annals of Internal Medicine.
[114] G. Eknoyan,et al. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[115] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[116] Karla Kerlikowske,et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.
[117] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[118] Z. Pausova,et al. Gene-environment interactions in hypertension , 1999, Current hypertension reports.
[119] I. U. Haq,et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.
[120] M. Moser. A critique of the world health organization-international society of hypertension guidelines for the management of hypertension , 1999 .
[121] J. Chalmers. Implementation of guidelines for management of hypertension. , 1999, Clinical and experimental hypertension.
[122] F. Luft,et al. Molecular genetics of human hypertension. , 1998, Current opinion in cardiology.
[123] J A Staessen,et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension , 1998, Journal of hypertension.
[124] A. Zanchetti,et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.
[125] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[126] T. Mori,et al. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. , 1998, Hypertension.
[127] R. Bigazzi,et al. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension , 1998, Journal of hypertension.
[128] A. Döring,et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. , 1998, European heart journal.
[129] K Nagai,et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. , 1998, Hypertension.
[130] Shigeru Hisamichi,et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan , 1998, Journal of hypertension.
[131] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[132] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[133] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[134] C. Furberg,et al. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. , 1998, Atherosclerosis.
[135] G. Parati,et al. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. , 1998, Hypertension.
[136] P. Whelton,et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.
[137] R. Schrier,et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.
[138] Beverley Balkau,et al. High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.
[139] R. Schmieder,et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[140] L. Hansson,et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. , 1998, Hypertension.
[141] R H Selzer,et al. The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.
[142] G. Reboldi,et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. , 1998, Circulation.
[143] J. Staessen,et al. Should exercise blood pressure be measured in clinical practice? , 1998, Journal of hypertension.
[144] A. Ganguly. Primary aldosteronism. , 1998, The New England journal of medicine.
[145] P. Thürmann,et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. , 1998, Circulation.
[146] A. Amos,et al. The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[147] L Guize,et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.
[148] T. Ohkubo,et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. , 1997, American journal of hypertension.
[149] Ralph B D'Agostino,et al. Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study , 1997, Diabetes.
[150] A. Zanchetti. The hypertensive patient with multiple risk factors: is treatment really so difficult? , 1997, American journal of hypertension.
[151] M. Woodward,et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study , 1997, BMJ.
[152] Jan A Staessen,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.
[153] Arno W. Hoes,et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.
[154] H. Gerstein,et al. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. , 1997, Archives of internal medicine.
[155] Y. Imai,et al. Reproducibility of home blood pressure measurements over a 1-year period. , 1997, American journal of hypertension.
[156] F. Magrini,et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[157] G. Jennings. Exercise and blood pressure: Walk, run or swim? , 1997, Journal of hypertension.
[158] R. Kronmal,et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1997, Stroke.
[159] A. Zanchetti. Antihypertensive therapy: how to evaluate the benefits. , 1997, The American journal of cardiology.
[160] J. Cutler,et al. Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men , 1997, Annals of Internal Medicine.
[161] I. Puddey,et al. Alcohol, hypertension and the cardiovascular system: a critical appraisal , 1997, Addiction biology.
[162] R. Doughty,et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.
[163] J. Tuomilehto,et al. Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid? , 1997, Journal of Human Hypertension.
[164] S. Haffner. The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. , 1997, Journal of diabetes and its complications.
[165] G Mancia,et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. , 1997, Circulation.
[166] R H Fagard,et al. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. , 1997, Hypertension.
[167] H. Drexler,et al. Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.
[168] K. Zarnke,et al. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. , 1997, American journal of hypertension.
[169] M. Law. Epidemiologic evidence on salt and blood pressure. , 1997, American journal of hypertension.
[170] J F Toole,et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1996, Stroke.
[171] M. Laakso,et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.
[172] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[173] P. Schollmeyer,et al. Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. , 1996, Kidney international.
[174] M. Rocco,et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.
[175] E. Grossman,et al. Diabetic and Hypertensive Heart Disease , 1996, Annals of Internal Medicine.
[176] J. Staessen,et al. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. , 1996, Hypertension.
[177] G. Mancia,et al. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. , 1996, Journal of hypertension.
[178] S. Fo,et al. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. , 1996 .
[179] S. Wannamethee,et al. Patterns of alcohol intake and risk of stroke in middle-aged British men. , 1996, Stroke.
[180] T. Ohkubo,et al. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, northern Japan. , 1996, Blood pressure monitoring.
[181] B. Lernfelt,et al. 15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.
[182] P. Hamet,et al. Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.
[183] S. Kjeldsen,et al. Exercise blood pressure predicts mortality from myocardial infarction. , 1996, Hypertension.
[184] B. Krämer,et al. Diagnostic strategies in renovascular hypertension. , 1996, Clinical nephrology.
[185] J. Laragh,et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. , 1996, Circulation.
[186] M. Kawi. Hypertension control. Report of a WHO Expert Committee. , 1996, World Health Organization technical report series.
[187] G. Mancia,et al. Ambulatory blood pressure normality: results from the PAMELA study , 1995, Journal of hypertension.
[188] A D Oxman,et al. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[189] J. Cutler,et al. Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .
[190] I. Puddey,et al. Exercise lowers blood pressure--sometimes? Or did Pheidippides have hypertension? , 1995, Journal of hypertension.
[191] D. Rizzoni,et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.
[192] P. Poole‐Wilson,et al. [Prevention of coronary disease in clinical practice. Recommendations of the Task-Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. , 1995, Annales de cardiologie et d'angeiologie.
[193] P Whelton,et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.
[194] I. Hjermann,et al. Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. , 1995, American journal of hypertension.
[195] S. Yusuf,et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.
[196] G. Colditz,et al. Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.
[197] D. Orth. Cushing's syndrome. , 1995, The New England journal of medicine.
[198] G. Parati,et al. Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.
[199] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[200] J. Laragh,et al. Diagnosis and Treatment of Primary Hyperaldosteronism , 1994, Annals of Internal Medicine.
[201] H. Parving,et al. Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V , 1994, Diabetes Care.
[202] R Doll,et al. Mortality in relation to smoking: 40 years' observations on male British doctors , 1994, BMJ.
[203] D. Levy,et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.
[204] S. Yusuf,et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.
[205] E. Bravo,et al. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.
[206] G. Parati,et al. Increase in blood pressure reproducibility by repeated semi‐automatic blood pressure measurements in the clinic environment , 1994, Journal of hypertension.
[207] M. Stowasser,et al. HIGH INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION , 1994, Clinical and experimental pharmacology & physiology.
[208] C. Reid,et al. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects , 1994, Journal of hypertension.
[209] D. Mant,et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.
[210] R. Collins,et al. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.
[211] J. Dillon. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[212] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[213] L. Ruilope,et al. Clinical relevance of proteinuria and microalbuminuria. , 1993, Current opinion in nephrology and hypertension.
[214] G Mancia,et al. Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.
[215] W. G. Walker. Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[216] J. Salonen,et al. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. , 1993, Circulation.
[217] K. Arakawa. Antihypertensive mechanism of exercise. , 1993, Journal of hypertension.
[218] K Rodahl,et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. , 1993, The New England journal of medicine.
[219] J. Staessen,et al. A meta-analysis of outcome trials in elderly hypertensives. , 1992, Journal of hypertension.
[220] R. Vandongen,et al. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. , 1992, Hypertension.
[221] M. Schroll,et al. The Glostrup Population Studies, 1964-1992. , 1992, Danish medical bulletin.
[222] R. J. Sjoberg,et al. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. , 1992, Archives of internal medicine.
[223] J. Sowers,et al. Diabetes mellitus and hypertension. , 1992, Hypertension.
[224] J. Staessen,et al. Mean and range of the ambulatory pressure in normotensive subjects. , 1992, Chinese medical journal.
[225] P. Sleight,et al. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension , 1992, Journal of hypertension.
[226] H. Köhler,et al. Acanthocyturia--a characteristic marker for glomerular bleeding. , 1991, Kidney international.
[227] J. Stamler,et al. Epidemiologic findings on body mass and blood pressure in adults. , 1991, Annals of epidemiology.
[228] J. Laragh,et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.
[229] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[230] Paul M. Vanhoutte,et al. The Endothelium: Modulator of Cardiovascular Function , 1990 .
[231] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[232] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[233] G. Schillaci,et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.
[234] S. Sans,et al. Recruitment methods and differences in early, late and non-respondents in the first MONICA-Catalonia population survey. , 1990, Revue d'epidemiologie et de sante publique.
[235] Ralph B. D'Agostino,et al. Blood Pressure as a Risk Factor for Cardiovascular Disease The Framingham Study—30 Years of Follow‐up , 1989, Hypertension.
[236] D. Simonson. Etiology and Prevalence of Hypertension in Diabetic Patients , 1988, Diabetes Care.
[237] T. Pickering,et al. Do laboratory tests of blood pressure reactivity predict blood pressure changes during everyday life? , 1988, American journal of hypertension.
[238] P. Wilson,et al. Incidence of Diabetic Retinopathy and Relationship to Baseline Plasma Glucose and Blood Pressure , 1988, Diabetes Care.
[239] J. Laragh,et al. How common is white coat hypertension? , 1988, JAMA.
[240] R. Vandongen,et al. REGULAR ALCOHOL USE RAISES BLOOD PRESSURE IN TREATED HYPERTENSIVE SUBJECTS A Randomised Controlled Trial , 1987, The Lancet.
[241] G Parati,et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.
[242] R. Vandongen,et al. Vegetarian diet in mild hypertension: a randomised controlled trial. , 1986, British medical journal.
[243] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[244] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.
[245] G. Parati,et al. Lack of alerting reactions to intermittent cuff inflations during noninvasive blood pressure monitoring. , 1985, Hypertension.
[246] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[247] S. M. Collins,et al. Ultrasonic backscatter and collagen in normal ventricular myocardium. , 1984, Circulation.
[248] [Drug management]. , 1984, Pielegniarka i polozna.
[249] C. Mogensen. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy , 1982, British medical journal.
[250] N. Reichek,et al. Left Ventricular Hypertrophy: Relationship of Anatomic, Echocardiographic and Electrocardiographic Findings , 1981, Circulation.
[251] F. Messerli,et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. , 1980, Annals of internal medicine.
[252] M. New,et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. , 1979, The Journal of clinical endocrinology and metabolism.
[253] N. M. Keith,et al. Some Different Types Of Essential Hypertension: Their Course And Prognosis , 1939, The American journal of the medical sciences.
[254] D. Sutherland,et al. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. , 1966, Canadian Medical Association journal.
[255] K. Thurau. RENAL HEMODYNAMICS. , 1964, The American journal of medicine.
[256] G. Perera. Hypertensive vascular disease; description and natural history. , 1955, Journal of chronic diseases.